Abstract
Aberrant activation of the Wnt/β-catenin pathway and polo-like kinase 1 (Plk1) overexpression represent two common events in prostate cancer with relevant functional implications. This minireview analyzes their potential therapeutic significance in prostate cancer based on their role as androgen receptor (AR) signaling regulators and the pivotal role of the tumor suppressor protein phosphatase 2A (PP2A) modulating these pathways.
Supplemental material for this article may be found at http://dx.doi.org/10.1128/MCB.00130-16.
ACKNOWLEDGMENTS
This work was supported by grants PI13/02609 and PI15/00934 from the Instituto de Salud Carlos III FEDER.
We declare that we have no conflict of interest.